Home・Aktien・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Geschlossen

22.1 -0.54

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

21.96

Max

22.39

Schlüsselkennzahlen
By Trading Economics
Einkommen	-6.4M -20M
Verkäufe	-807K 71M
EPS	-0.13
Gewinnspanne	-28.24
Angestellte	624
EBITDA	-7.9M -14M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	-2.69% downside

Dividenden
By Acuity
Nächstes Ergebnis	29. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.2B 3.5B
Vorheriger Eröffnungskurs	22.64
Vorheriger Schlusskurs	22.1

Adaptive Biotechnologies Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Juli 2026, 23:51 UTC

Correlated Moves

Bitcoin is trading higher during Saturday's session, building on Friday's gains. The price movement aligns with Ethereum's upward trend.

25. Juli 2026, 23:42 UTC

Personal Income MoM Data Release on July 30, 2026, Forecasts Modest Growth Amid Ongoing Market Volatility and Geopolitical Concerns.

25. Juli 2026, 23:42 UTC

U.S. Personal Spending Expected to Rise 0.4% in June Amid Inflation and Geopolitical Tensions Impacting Consumer Behavior

25. Juli 2026, 23:42 UTC

Market Awaits Key PCE Price Index Data on July 30, 2026, Amid Rising Inflation Concerns and Potential Impact on Federal Reserve Policy.

25. Juli 2026, 23:42 UTC

South Korea's exports surge 70.9% in June, with August release expected to reveal continued growth amid cautious investor sentiment due to inflation and geopolitical tensions.

25. Juli 2026, 23:42 UTC

U.S. GDP Price Index Set for 3.7% Increase Amid Cautious Optimism and Inflation Concerns Ahead of Key Federal Reserve Policy Decisions.

25. Juli 2026, 23:42 UTC

Traders Brace for PCE Price Index Release Amid Geopolitical Tensions and Inflation Concerns, Anticipating 0.4% Increase

25. Juli 2026, 23:42 UTC

Core PCE Price Index MoM Release on July 30, 2026, Expected to Show Modest 0.1% Increase Amid Inflation Concerns and Market Sensitivity.

25. Juli 2026, 23:42 UTC

U.S. Q2 2026 GDP Growth Rate Release Expected at 2.3% Amid Positive Economic Sentiment and Geopolitical Concerns

25. Juli 2026, 23:32 UTC

S&P/Case-Shiller Home Price Index Set for July Release Amidst Cautious Market Sentiment and Inflation Concerns

25. Juli 2026, 23:32 UTC

South Africa's upcoming balance of trade data on July 31, 2026, is under scrutiny as analysts anticipate continued deficits amid rising imports and geopolitical tensions.

25. Juli 2026, 23:31 UTC

"Cryptocurrency Gains Amid Geopolitical Tensions; European Stocks Shift and Fed's Rate Decision Looms"

25. Juli 2026, 23:31 UTC

Cryptocurrency gains amid European market reassessment and bond turmoil, as investors brace for the Fed's interest rate decision and Japan's fiscal policy shift.

25. Juli 2026, 23:31 UTC

Bitcoin and Ethereum rise amid shifting European equity markets, Japan's fiscal policy changes, and looming Federal Reserve interest rate decision.

25. Juli 2026, 23:31 UTC

Cryptocurrency prices rise as Bitcoin and Ethereum gain, while European equity markets face shifts and Japan's fiscal policy change looms ahead of the Federal Reserve's interest rate decision.

25. Juli 2026, 23:24 UTC

Mexico's Q2 GDP Growth Rate Release on July 30 Sparks Cautious Optimism Amid Strong Services PMI Performance.

25. Juli 2026, 23:24 UTC

Brazil's Unemployment Rate Expected to Remain Stable or Improve in June 2026 Amid Cautious Optimism and Economic Recovery Concerns

25. Juli 2026, 23:13 UTC

Mexico's Q2 2026 GDP Growth Rate Release on July 30 Sparks Caution Amid Geopolitical Tensions and Trade Tariff Concerns.

25. Juli 2026, 23:13 UTC

Japan's Industrial Production MoM data for June 2026 set to release on July 30, with a modest increase of 0.7% anticipated amid mixed economic sentiment and rising inflation concerns.

25. Juli 2026, 23:13 UTC

Germany's Inflation Rate Release on July 30, 2026: Market Anticipates Continued Pressure Amid Mixed Economic Signals.

25. Juli 2026, 23:13 UTC

Japan's Retail Sales Expected to Rise 2.8% YoY Amid Concerns Over Consumer Spending and Economic Recovery Challenges

25. Juli 2026, 23:13 UTC

Germany's July Inflation Rate Expected to Rise 0.7% Amid Mixed Economic Sentiment and Rising Oil Prices

25. Juli 2026, 23:03 UTC

Wholesale Inventories MoM Advance Data Set for Release Amid Mixed Economic Sentiment and Geopolitical Tensions, Forecasting 0.2% Increase.

25. Juli 2026, 23:03 UTC

U.S. Goods Trade Balance Release Expected to Show $98 Billion Deficit Amid Tariff Concerns and Inflation Pressures

25. Juli 2026, 23:03 UTC

U.S. Retail Inventories Ex Autos Data Release on July 28, Amid Weakening Consumer Spending and Inflation Concerns

25. Juli 2026, 23:01 UTC

Avalanche continues to trade higher, reflecting strong performance since Friday's close. Earlier, it peaked over 8%, remaining above its 20-day moving average.

25. Juli 2026, 22:51 UTC

Japan's June 2026 unemployment rate forecast at 2.5% amid rising inflation concerns and market volatility ahead of release on July 30, signaling mixed investor sentiment.

25. Juli 2026, 22:42 UTC

Durable Goods Orders Report on July 27, 2026 Expected to Show Recovery Amidst Market Volatility and Geopolitical Tensions.

25. Juli 2026, 22:42 UTC

U.S. Durable Goods Orders Ex Transportation Expected to Rise 0.9% in June Amid Cautious Optimism and External Economic Pressures

25. Juli 2026, 22:42 UTC

Mortgage Rates Hit 6.69% Amid Rising Treasury Yields and Inflation Concerns, Influencing Real Estate Market Dynamics

Peer-Vergleich

Kursveränderung

Adaptive Biotechnologies Corp Prognose

Kursziel

By TipRanks

-2.69% Nachteil

12-Monats-Prognose

Durchschnitt 21.67 USD -2.69%

Hoch 25 USD

Tief 19 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Adaptive Biotechnologies Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Adaptive Biotechnologies Corp – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.